December 19, 2025 – Oxford UK
After a year of steady progress, AlveoGene is pleased to provide an update on the progress of its pipeline of inhaled gene therapy development candidates targeting rare respiratory disease enabled by its InGenuiTy® platform.
AlveoGene has generated world leading pre-clinical data in SP-B surfactant protein deficiency (AVG-002), is progressing data in ABCA3 surfactant protein deficiency at pace (AVG-003), and data for AATD-Lung disease (AVG-001) supports a future market leading product.
In combination, these data provides additional Investor confidence in support of our current Series A financing and we look forward to meeting Investors and partners during JPM week in San Francisco, USA week commencing 12 January 2026.
This update is provided in the form of a short narrated presentation embedded below.
For for information please visit www.alveogene.com